Gilead Sciences, Inc. (GILD) Stock

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Gilead Sciences, Inc. is led by CEO Daniel O'Day, employs 17,600 people, headquartered in Foster City, US, publicly traded since 1992.

Gilead Sciences, Inc. (GILD) stock trades at $132.73 with a market capitalization of $164.79B. The stock is valued at a price-to-earnings (P/E) ratio of 17.57, price-to-book of 6.82, price-to-sales of 5.39. Over the past 52 weeks the stock has ranged between $93.37 and $157.29, and currently trades 15.6% below its 52-week high. It pays a dividend yielding 2.46%.

On profitability, Gilead Sciences, Inc. generates a return on equity (ROE) of 43.36% — well above the market average, a sign of a high-quality business, return on capital employed of 51.73%, an operating margin of 39.74%, a net profit margin of 30.99%.

In its most recent fiscal year, Gilead Sciences, Inc. reported annual revenue of $29.4B, net profit of $8.5B, revenue has compounded at 3.6% a year over the last five years, profit at 133.3% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.95, a current ratio of 1.68, total assets of $59.0B, $7.6B in cash and equivalents.

GILD has an average daily trading volume of 7,534,129 shares, a beta of 0.33 (less volatile than the overall market).

Official website: www.gilead.com